Skip to content
  • Contact Us
  • Request Samples
  • Order
Mill Creek Life Sciences
  • Our Technology
    • Human Platelet Lysate
    • Applications
    • Dendritic Cell Vaccine
  • Products
    • PLTMax®
    • PLTGold®
    • Order
    • Request Samples
  • Support
    • Technical Support
    • Publications
    • Posters
    • Distributors
    • FAQs
    • Contact Us
  • About Us
    • Our Company
    • Quality
    • News
    • Collaborate
    • Careers
Filters (17)
Filters
  • Reset all ×
  • Clinical trials ×

17 resources found

Show (17)
Cancel

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma (Jun 2022)

Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (Oct 2022)

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial (May 2021)

In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure (Apr 2020)

CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury (Feb 2020)

Matrix-Delivered Autologous Mesenchymal Stem Cell Therapy for Refractory Rectovaginal Crohn’s Fistulas (Apr 2020)

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (Sep 2019)

Targeting senescence improves angiogenic potential of adipose-derived mesenchymal stem cells in patients with preeclampsia (Sep 2019)

Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy (Jul 2019)

Early Results of a Phase I Trial Using an Adipose-Derived Mesenchymal Stem Cell-Coated Fistula Plug for the Treatment of Transsphincteric Cryptoglandular Fistulas (May 2019)

Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease (Sep 2017)

Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn’s Disease (Jul 2017)

Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenic women following a one-year double-blind RCT and on osteoblast-osteoclast co-cultures (Jan 2017)

Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS (Nov 2016)

Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells (Oct 2016)

Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics (Jun 2013)

Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer (Jan 2013)

MillCreekLifeSciences_StackedWhite-01

221 1st Avenue SW, Suite 209 Rochester, Minnesota 55902, USA

Phone: 507-287-6257
Fax: 507-289-2066
Email: info@millcreekls.com

OUR TECHNOLOGY

Human Platelet Lysate

Applications

Dendritic Cell Vaccine

PRODUCTS

PLTMax®

PLTGold®

Order

Request Samples

SUPPORT

Technical Support

Publications

Posters

Distributors

FAQs

Contact Us

ABOUT US

Our Company

Quality

News

Collaborate

Careers